NALIRIFOX chemo for advanced neuroendocrine cancer after first treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination chemotherapy called NALIRIFOX as a second treatment for people with advanced high-grade neuroendocrine cancers. The goal is to see if it can help when the first treatment didn't work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a high-grade neuroendocrine cancer (such as neuroendocrine carcinoma or neuroendocrine tumor G3) that has spread to other parts of your body.
- You must have already received one prior treatment for your cancer and it stopped working.
- You must be in fairly good health (able to do light work or be fully active).
- You must have adequate kidney, liver, and blood cell counts (checked with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a combination of four chemotherapy drugs (NALIRIFOX) as a first treatment for people with advanced appendix or small intestine cancer. It aims to see if this combination is safe and effective.
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
Hear when a new NENS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.